Advertisement


Holger N. Lode, MD: Neuroblastoma Survival Update

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor genotypes and Fc-receptor polymorphisms. (Abstract 111)



Related Videos

Skin Cancer

Marie-Andrée Forget, PhD, on Metastatic Melanoma: Update From MD Anderson

Marie-Andrée Forget, PhD, of The University of Texas MD Anderson Cancer Center, discusses study findings on the impact of checkpoint blockade prior to adoptive cell therapy using tumo...

CNS Cancers

Holger N. Lode, MD: Neuroblastoma Survival Update (German Language Version)

Holger N. Lode, MD, of the University of Greifswald, discusses in German the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO an...

Issues in Oncology

Lawrence Fong, MD, on Novel T-Cell Checkpoint Combinations

Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.

Solid Tumors

Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy

Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.

Solid Tumors

Stephen Gottschalk, MD, on CAR T Cells for Solid Tumors: What Are the Challenges?

Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their a...

Advertisement

Advertisement



Advertisement